 |
Matthew Ciorba, M.D.
|
|
Matthew Ciorba, M.D. Instructor in Medicine Dr. Ciorba joined the faculty and the Inflammatory Bowel Disease Program in 2007. He came to Washington University initially for residency in Internal Medicine after medical school at the University of Iowa's Carver College of Medicine. Following a chief residency at the John Cochrane VA Hospital, he completed gastroenterology fellowship training through Washington University and Barnes Jewish Hospital. He received additional fellowship training at the Inflammatory Bowel Disease Center of Mount Sinai Hospital in New York City. His clinical focus and research are both centered on the Inflammatory Bowel Diseases. He also has a particular interest in the potential of Probiotics based therapies and their potential application to intestinal disorders. "My main clinical focus is to provide comprehensive care to patients affected by one of the Inflammatory Bowel Diseases (IBD), including Crohn's Disease and Ulcerative Colitis. By using evidence based approaches to our current standard of care medications, along with newer biologic therapies and the trials available in our IBD Center, I strive to maximize the individuals overall well being and reduce the need for surgery.” “My laboratory research is focused on understanding mechanisms involved in modulating intestinal inflammation and response to injury. Along with Drs. Stenson and Newberry in our division, I am furthering investigations into a specific enzyme, Indoleamine 2,3 Dixoygenase (IDO), which has been demonstrated to have potent immune modulating capacity. Our findings have suggested that IDO is an important regulator of the intestinal inflammatory response. IDO is found to have increased expression in both human and animal models of IBD. Blocking this enzyme leads to worsened inflammation. We are now showing that pharmacologic upregulation of intestinal IDO expression may have therapeutic potential in inflammatory bowel disease. This ongoing work is supported by the NIDDK/DDRCC at Washington University and a career development award from the Crohn's and Colitis Foundation of America. Also, with support from the Global Probiotics Council, our lab has also developed evidence showing that certain probiotic bacteria may have a role in limiting radiation induced small bowel injury and its associated symptoms. Translation of this work to treating human disease is in development.”
Link to Medline for selected publications
Division of Gastroenterology
|
